Table 1.
Characteristics of postmenopausal CAD patients in the three groups divided by SIRI tertiles.
| Variables | Low level SIRI | Intermediate level SIRI | High level SIRI | p-value |
|---|---|---|---|---|
| (SIRI <0.73) | (1.29≥ SIRI <0.73) | (SIRI ≥1.29) | ||
| SIRI | ||||
| Age, years | 63.98 ± 8.27 | 65.60 ± 8.42 | 67.75 ± 8.91 | <0.001 |
| WBC (×109/L) | 5.22 ± 1.31 | 6.19 ± 1.35 | 8.31 ± 2.64 | <0.001 |
| Neut (×109/L) | 2.86 ± 0.87 | 3.84 ± 0.88 | 6.17 ± 2.55 | <0.001 |
| Mono (×109/L) | 0.34 ± 0.09 | 0.44 ± 0.11 | 0.55 ± 0.18 | <0.001 |
| Lymph (×109/L) | 1.87 ± 0.62 | 1.73 ± 0.56 | 1.47 ± 0.53 | <0.001 |
| Hb (g/L) | 122.72 ± 14.69 | 123.13 ± 13.33 | 121.35 ± 14.36 | 0.414 |
| PLT (×109/L) | 221.10 ± 60.98 | 225.54 ± 63.17 | 242.48 ± 73.79 | 0.003 |
| TC (mmol/L) | 4.17 ± 1.12 | 3.98 ± 0.96 | 4.02 ± 1.1 | 0.192 |
| TG (mmol/L) | 1.75 ± 1.43 | 1.84 ± 1.1 | 1.55 ± 0.88 | 0.038 |
| HDL-C (mmol/L) | 1.15 ± 0.28 | 1.09 ± 0.25 | 1.14 ± 0.27 | 0.048 |
| LDL-C (mmol/L) | 2.45 ± 0.97 | 2.31 ± 0.8 | 2.37 ± 0.95 | 0.281 |
| Fib (g/L) | 2.90 ± 0.52 | 3.15 ± 0.61 | 3.46 ± 0.98 | <0.001 |
| D-Dimer (mg/L) | 0.25 ± 0.45 | 0.31 ± 0.68 | 0.45 ± 1.52 | 0.101 |
| Cr (µmol/L) | 63.09 ± 30.9 | 65.17 ± 20.04 | 70.88 ± 41.41 | 0.039 |
| BUN (mmol/L) | 5.52 ± 1.78 | 5.61 ± 1.91 | 6.84 ± 10.85 | 0.069 |
| UA (µmol/L) | 284.41 ± 81.81 | 295.62 ± 83.8 | 297.11 ± 99.59 | 0.285 |
| ALT (U/L) | 23.24 ± 21.29 | 28.74 ± 53.17 | 31.03 ± 43.07 | 0.149 |
| AST (U/L) | 29.06 ± 26.3 | 32.03 ± 43.07 | 53.95 ± 103.86 | <0.001 |
| TBIL (µmol/L) | 9.14 ± 3.51 | 9.83 ± 5.41 | 10.06 ± 4.73 | 0.113 |
| DBIL (µmol/L) | 3.83 ± 1.6 | 4.13 ± 2.77 | 4.27 ± 2.23 | 0.128 |
| IBIL (µmol/L) | 5.25 ± 2.38 | 5.50 ± 2.94 | 5.75 ± 3.29 | 0.208 |
| Alb (g/L) | 41.89 ± 4.15 | 41.68 ± 3.42 | 40.07 ± 4.28 | <0.001 |
| FPG (mmol/L) | 5.94 ± 2.5 | 6.40 ± 2.54 | 7.13 ± 3.57 | <0.001 |
| HbA1c (%) | 6.43 ± 1.25 | 6.79 ± 1.32 | 6.70 ± 1.46 | 0.030 |
| Hypertension (n,%) | 138 (37.0) | 147 (71.7) | 147 (71.4) | 0.508 |
| Diabetes (n,%) | 56 (27.2) | 79 (38.5) | 70 (34.0) | 0.049 |
| AF (n,%) | 6 (2.9) | 11 (5.4) | 14 (5) | 0.189 |
| Number of lesions (n,%) | ||||
| 1-VD | 58 (28.2) | 43 (21.0) | 28 (13.6) | 0.001 |
| 2-VD | 53 (25.7) | 49 (23.9) | 62 (30.1) | 0.344 |
| 3-VD | 95 (46.1) | 114 (55.6) | 117 (56.8) | 0.059 |
| LM | 13 (6.3) | 14 (6.8) | 19 (9.2) | 0.487 |
| Medication use (n,%) | ||||
| Antiplatelet drugs | 206 (100) | 205 (100) | 206 (100) | 1.000 |
| Statins | 206 (100) | 205 (100) | 206 (100) | 1.000 |
| β-blockers | 68 (33.0) | 57 (27.8) | 50 (24.3) | 0.141 |
| ACEI or ARB | 103 (50.0) | 96 (46.8) | 78 (37.9) | 0.037 |
WBC, white blood cell; Neut, neutrophil; Mono, monocyte; Lymph, lymphocyte; Hb, hemoglobin; PLT, platelet; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Fib, fibrinogen; Cr, creatinine; BUN, blood urea nitrogen; UA, uric acid; ALT, alanine transaminase; AST, aspartate transaminase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; Alb, albumin; FPG, fasting blood glucose; HbA1c, glycosylated hemoglobin; AF, atrial fibrillation; LM, left main trunk lesion; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotonin receptor blocker.